Literature DB >> 11516108

Atypical lymphocytic leukemia and mantle cell lymphoma immunologically very close: flow cytometric distinction by the use of CD20 and CD54 expression.

V Deneys1, L Michaux, P Leveugle, A M Mazzon, E Gillis, A Ferrant, J M Scheiff, M De Bruyère.   

Abstract

Integration of morphological and immunophenotypic data is critical in achieving diagnosis accuracy and minimising interobserver interpretative discrepancies. The aim of this work was to compare the immunophenotype and the morphology of chronic lymphocytic leukaemia and mantle cell lymphoma, to help in the differential diagnosis of CD5 positive monoclonal B cells. Frozen/thawed samples from 91 patients were analysed retrospectively. Fresh samples from 17 mixed/atypical CLL and 13 MCL were tested to corroborate the results. Markers were analysed as percentage (%) of positive B lymphocyte subpopulation, and in terms of median fluorescence intensity (MFI). Matutes's CLL score clearly allowed distinguishing between classical CLL on the one hand, and atypical CLL and MCL on the other hand. The percentage of CD54-positive cells and the median fluorescence intensity of CD20 and CD54 were the only parameters which were significantly higher in MCL than in atypical CLL (P < 0.05), allowing an immunological distinction between these two entities. Nevertheless, due to a quenching problem when using CD20 and CD54 together, and because CD18 showed a statistically different expression between classical and atypical CLL, the combination of CD18/CD54 has been preferred and showed a different pattern in the three entities. Immunophenotyping could be helpful in the differential diagnosis of CD5-positive B cell chronic lymphoproliferative disorders with atypical features that do not fit exactly into any of the morphologic proposed groups.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11516108     DOI: 10.1038/sj.leu.2402200

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  4 in total

1.  Differential and tumor-specific expression of CD160 in B-cell malignancies.

Authors:  Timothy W Farren; Jerome Giustiniani; Feng-Ting Liu; Dimitris A Tsitsikas; Marion G Macey; James D Cavenagh; Heather E Oakervee; David Taussig; Adrian C Newland; Maria Calaminici; Armand Bensussan; Michael Jenner; John G Gribben; Samir G Agrawal
Journal:  Blood       Date:  2011-06-28       Impact factor: 22.113

2.  Automated analysis of multidimensional flow cytometry data improves diagnostic accuracy between mantle cell lymphoma and small lymphocytic lymphoma.

Authors:  Habil Zare; Ali Bashashati; Robert Kridel; Nima Aghaeepour; Gholamreza Haffari; Joseph M Connors; Randy D Gascoyne; Arvind Gupta; Ryan R Brinkman; Andrew P Weng
Journal:  Am J Clin Pathol       Date:  2012-01       Impact factor: 2.493

3.  The potential differential diagnosis value and clinical significance of CD35 expression in B-chronic lymphoproliferative disorders.

Authors:  Yu Shi; Lu Liu; Hui Yang; Xiao Chen; Yan Wang; Sishu Zhao; Huimin Jin; Yujie Wu
Journal:  Ann Transl Med       Date:  2021-07

4.  The Role of CD200 and CD43 Expression in Differential Diagnosis between Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma.

Authors:  Mesude Falay; Berna Afacan Öztürk; Kürşad Güneş; Yasin Kalpakçı; Simten Dağdaş; Funda Ceran; Gülsüm Özet
Journal:  Turk J Haematol       Date:  2017-07-17       Impact factor: 1.831

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.